Dr. Anatoly Dritschilo, MD
Dr. Anatoly Dritschilo, MD completed his training in radiation oncology at Harvard Medical School and served as a faculty member at the Tufts University School of Medicine, Boston before joining the Georgetown University Medical Center (GUMC). He is a Diplomate of the American Board of Radiology and a Fellow of the American College of Radiology. He has over 35 years of experience as a physician-scientist and radiation oncologist, specializing in the treatment of breast and prostate cancer, radiation medicine, intraoperative radiation therapy, brachytherapy, 3D conformal radiotherapy, and development of radiation sensitizers for more effective cancer therapy. He is a NIH-funded translational physician-scientist and has published more than 200 research articles in high impact medical and scientific journals regarding the basic molecular mechanisms of cancer and the clinical translation of laboratory research to patient care.
Dr. Anatoly Dritschilo has served as Professor and Chairman, Department of Radiation Medicine, Georgetown University School of Medicine, Washington, D.C for more than 30 years. From 2005 to 2007 Dr. Dritschilo, served as Interim Director of the Vincent T. Lombardi Comprehensive Cancer Center and interim Chair of the Department of Oncology at the Georgetown University Medical Center (GUMC). In 2005, he was re-appointed to Chairmanof the Department of Radiation Medicine, at the Georgetown University School of Medicine, and Chief of the Radiation Oncology Service at MedStar Georgetown University Hospital, in 2010. Under his leadership, the MedStar-Georgetown Radiation Oncology Program was one of the first to establish a CyberKnife radiation therapy program and a Mevion proton therapy site.
Dr. Dritschilo has served as an advisor to the NIH and the American Cancer Society on research funding and also has served on the Board of Directors of the National Coalition for Cancer Research, on the Roster of Distinguished Scientific Advisors to the Radiological Society of North America. He is a member of the American Association of Cancer Research, American Society for Clinical Oncologists, American Society of Therapeutic Radiation Oncologists and the Radiation Research Society. Dr. Dritschilo is also a co-inventor of patents in radiosurgery and stereotactic radiation therapy methods, radiation sensitizing drugs and personalized methods of treatment of cancer patients. Dr. Dritschilo co-founded Shuttle Pharmaceuticals, LLC in December 2012 and has served as its Chairman of the Board and Chief Executive Officer since then.